Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
SEATTLE, Nov. 23, 2016 -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it will present at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 1:00 pm EST at the Lotte New York Palace Hotel.
A live audio webcast of the presentation can be accessed at www.aptevotherapeutics.com under the ‘Investors’ section of the website, under ‘Events.’ An audio reply of the webcast will be available following the live webcast.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. Aptevo has four commercial products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.
Source:
Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications
206-859-6628
[email protected]
